Safety and Efficacy of the GTS400 Stent in Conjunction With Cataract
Primary Purpose
Open-angle Glaucoma
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Glaucoma Stent Surgery (GTS400 Stent)
cataract surgery alone
Sponsored by
About this trial
This is an interventional treatment trial for Open-angle Glaucoma focused on measuring Open angle, Glaucoma, Cataract, Surgery
Eligibility Criteria
Inclusion Criteria:
- Mild to moderate Open-Angle Glaucoma with specific criteria, in need of cataract surgery
- Subject willing to attend scheduled follow-up exams for two years postoperatively, Subject willing to provide written informed consent on the Institutional Review Board approved Informed Consent Form
Exclusion Criteria:
Not meeting inclusion criteria
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
1
2
Arm Description
Treatment Group (Group 1): Glaukos Trabecular Micro-Bypass Stent Model GTS400; implantation in conjunction with cataract surgery
Control Group (Group 2): Cataract surgery only
Outcomes
Primary Outcome Measures
Month 12 Intraocular Pressure ≤ 18 mmHg Without Topical Hypotensive Medications
Percent reaching this endpoint
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00721968
Brief Title
Safety and Efficacy of the GTS400 Stent in Conjunction With Cataract
Official Title
A Prospective, Randomized, Controlled, Parallel Groups, Multicenter Clinical Investigation Of The Trabecular Micro-Bypass Stent Model GTS400 In Conjunction With Cataract Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
February 2014
Overall Recruitment Status
Completed
Study Start Date
March 2007 (undefined)
Primary Completion Date
February 2012 (Actual)
Study Completion Date
August 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Glaukos Corporation
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
To evaluate the safety and efficacy of the Glaukos Trabecular Micro-Bypass Stent Model GTS400 in conjunction with cataract surgery, compared to cataract surgery only, in subjects with mild to moderate open angle glaucoma.
Detailed Description
The objective of this trial is to evaluate the safety and efficacy of the Glaukos Trabecular Micro-Bypass Stent Model GTS400 (hereinafter referred to as GTS400) in combination with cataract surgery, compared to cataract surgery only, in subjects with mild to moderate primary open-angle glaucoma. This is a prospective, randomized, concurrently controlled, parallel groups, multicenter clinical investigation of the GTS400. Treatment will consist of either implantation of GTS400 stents in the study eye in conjunction with cataract surgery (Group 1, Investigational Group), or cataract surgery only (Group 2, Control Group). Clinical data through 12 months postoperative will form the basis of a pre-market approval (PMA) submission. Subjects will be followed for two years postoperatively.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Open-angle Glaucoma
Keywords
Open angle, Glaucoma, Cataract, Surgery
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
62 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Active Comparator
Arm Description
Treatment Group (Group 1): Glaukos Trabecular Micro-Bypass Stent Model GTS400; implantation in conjunction with cataract surgery
Arm Title
2
Arm Type
Placebo Comparator
Arm Description
Control Group (Group 2): Cataract surgery only
Intervention Type
Device
Intervention Name(s)
Glaucoma Stent Surgery (GTS400 Stent)
Other Intervention Name(s)
GTS400 Stent
Intervention Description
ab interno trabecular bypass stent surgery
Intervention Type
Procedure
Intervention Name(s)
cataract surgery alone
Other Intervention Name(s)
Phacoemulsification
Intervention Description
Cataract surgery alone
Primary Outcome Measure Information:
Title
Month 12 Intraocular Pressure ≤ 18 mmHg Without Topical Hypotensive Medications
Description
Percent reaching this endpoint
Time Frame
12 months
Other Pre-specified Outcome Measures:
Title
Number of Ocular Hypotensive Medications by Visit
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Mild to moderate Open-Angle Glaucoma with specific criteria, in need of cataract surgery
Subject willing to attend scheduled follow-up exams for two years postoperatively, Subject willing to provide written informed consent on the Institutional Review Board approved Informed Consent Form
Exclusion Criteria:
Not meeting inclusion criteria
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Head of Clinical Affairs
Organizational Affiliation
Glaukos Corporation
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
Safety and Efficacy of the GTS400 Stent in Conjunction With Cataract
We'll reach out to this number within 24 hrs